Search

Simoctocog alfa

As patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures … Simoctocog alfa is a glycoprotein consisting of 1440 amino acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length

Ergoloid mesylate

[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [T90] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives

Lacidipine

Due to its long duration of action, lacidipine does not lead to reflex tachycardia [A31536]. … It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved.

Tetrachlorodecaoxide

The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the … The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer.

Dosulepin

It is not FDA-approved due to low therpeutic index and significant toxicity in overdose. … The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies.

Technetium Tc-99m etidronate

Diethylstilbestrol

According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. … (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]

Kappadione

Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544]. … It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544].

Aducanumab

the data [A235720] and aducanumab was granted accelerated FDA approval on 7 June 2021. … [A235668] Based on Mini-Mental State Examination and Clinical Dementia Rating (CDR), patients taking aducanumab showed signs of slowing progression; however, these data were controversial.

Dexrazoxane

[PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. … It appears to inhibit formation of a toxic iron-anthracycline complex.